Loading...
Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America
BACKGROUND: In the CYD14 and CYD15 Phase 3 trials of the CYD-TDV dengue vaccine, estimated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue (VCD) occurring between months 13 and 25 was 56.5% and 60.8%, respectively. METHODS: Neutralizing antibody titers to the 4 dengue serot...
Na minha lista:
| Udgivet i: | J Infect Dis |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2018
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5854020/ https://ncbi.nlm.nih.gov/pubmed/29194547 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/infdis/jix609 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|